CBO @OSTherapies $OSTX, Interim Co-CEO @ Wellgistics $WGRX, CEO @ Amarantus, Founder @ TolloHealth @stanfordfball #girldad #Habs #Galectovid #Tollovid

Joined December 2012
539 Photos and videos
Gerald Commissiong retweeted
📢Some small progress updates on Hummingbird, Novavax’s large phase 2b/3 trial to study the safety and immunogenicity of Nuvaxovid in children aged 6 months to 12 years: 1. On April 29th, the FDA updated its postmarketing commitment database (which it does quarterly), and in that update, they reported that: • Novavax/Sanofi had requested an extension for Hummingbird on December 4th, which was granted by FDA on January 15th • As such, the projected date for the final report submission shifted from March 4th to May 22nd 2. The Hummingbird trial listing on ClinicalTrials.gov was indeed updated on that same projected date (May 22nd), for the first time since 2024, to shift from “Active, not recruiting” to “Completed”. Finally looks like some real progress, to me. Keep in mind that this trial alone was originally deemed good enough by the FDA to support an expansion of the label to pediatric populations, before FDA commissioner Makary and CBER director Prasad put in place a requirement for an additional immunogenicity study. Those guys are long gone now, and the rumor on the street is that RFK Jr. might not be far behind. FDA PMC database: accessdata.fda.gov/scripts/c… Trial listing: clinicaltrials.gov/study/NCT…
🧵💉A summary / reminder of where we stand on pediatric Novavax / Nuvaxovid access as of April 2026: We still haven’t heard anything regarding results from Novavax’s large pediatric trial (Hummingbird), which is running fairly late at this point. Per FDA docs (fda.gov/media/186545/downloa…), Hummingbird had an expected completion date of Oct. 28, 2025 and a Final Report Submission date of Mar. 4th, 2026. Here is the trial page where any results would first be made available: clinicaltrials.gov/study/NCT… Trump’s FDA has also instituted a new requirement for an additional immunogenicity study to support expansion to <12s. That new study has a completion date of Dec. 31, 2027 and a Final Report date of July 31, 2028. So, if nothing changes, and everything goes according to plan, we’re likely be looking at pediatric approval for the fall 2028 season. You can check the status of FDA postmarketing commitments here: accessdata.fda.gov/scripts/c… Hummingbird is still listed as “Ongoing” and the 2nd immunogenicity study is listed as “Pending: The study has not been initiated but does not meet the criterion for delayed.” I’m not sure how diligent manufacturers or FDA are about updating those statuses. Of course, Nuvaxovid, following last May’s BLA approval, is now able to be used off-label for pediatric use. And the wait is entirely too long, so in the meantime, the better bets are going to be: • As mentioned, working within the off-label framework and educating patients, providers, and pharmacies; creating reliable lists of friendly providers; etc. • Other groups having success in getting mRNA vaccines removed from the market, or at least an ACIP recommendation against them, and successfully steering that conversation in a direction that results in an immediate pediatric expansion. • Getting RFK Jr impeached and removed from office after the midterms, and removing the requirement for the additional immunogenicity study. • A pressure campaign aimed the new CBER director (who has not been announced yet - Prasad is leaving at the end of April) to remove the additional immunogenicity requirement, even in the absence of RFK’s removal. When talking to providers in attempt to get a pediatric prescription, folks can mention: • Japan has lowered the indication to ages 6 : ir.novavax.com/press-release… • A successful, completed pediatric safety and immunogenicity trial from India: pmc.ncbi.nlm.nih.gov/article… • A large safety study regarding the same dose Matrix-M adjuvant from the R21 malaria vaccine: thelancet.com/journals/lance… • Ongoing administration of that vaccine, which has now been administered to millions of kids in Africa down to 5 months of age and has been successful at cutting the Malaria rate by 50%: gavi.org/vaccineswork/kebbi-… • Novavax’s Hummingbird trial, which, while we have no data yet, obviously has no major safety signals, or else it would’ve been promptly reported on. We also have Reddit user /u/MilkThistleGenus in the community, a provider who has been super helpful at facilitating the process for many, through prescriptions & administration. After someone does have a prescription, finding a pharmacy that will administer can still be tough. It’s surprisingly the much harder part. We’ve heard many accounts at this point of pediatricians who are willing to look at the information and write a prescription, but many less pharmacies who are willing to fulfill them. Obviously, the best bet is going to be independent pharmacies, but we’ve also heard of success at Costco and Kroger-owned stores (specifically Smith’s) when it comes to chains, suggesting that there’s not necessarily a blanket policy against administration in many cases. Here is a helpful thread from someone who got administration at Costco, which is a nice summary of most things that I’ve already mentioned here, and they even created a Google doc with the studies that I’ve provided so that someone can easily send them to their provider: x.com/criticalaerosol/status…
4
23
130
5,743
Gerald Commissiong retweeted
OS Therapies is advancing OST-HER2, a Listeria-based immunotherapy in development designed to stimulate an immune response against HER2-expressing tumor cells in osteosarcoma. Explore the platform: ostherapies.com/technology/ $OSTX
2
13
265
Gerald Commissiong retweeted
Take note the increase in RSV cases. I continue to become more concerned with that virus for us here in the US next winter.
Victorian Weekly Respiratory Surveillance Report: 12 June 2026 From 31 May to 6 June 2026: 🔸COVID positivity rate: 2.2% (-0.7%) 🔹COVID: 376 (-10%) 🔹Influenza A: 162 ( 9%) 🔹Influenza B: 37 (-10%) 🔹RSV: 1088 ( 23%) Source: health.vic.gov.au/infectious…
4
34
1,012
Gerald Commissiong retweeted
OS Therapies is evaluating immune response data from its OST-HER2 program to better understand how treatment-related immune activity may correlate with clinical outcomes in osteosarcoma. The company analyzes biomarker signals observed during clinical studies as part of broader evaluation of OST-HER2 and its interaction with the immune system. Learn more: bit.ly/3QX7irr $OSTX
3
14
195
Gerald Commissiong retweeted
Replying to @Emma40025133
Have you tried Tollovid? It helped me but is not a cure. First time I did IVctin I responded overnight so inflammation is at play. Low dose statins can help. These are easy to access B 12 suits essential. Shots only
1
1
1
128
Gerald Commissiong retweeted
Replying to @Djae62525626
Tollovid is an herbal antiviral protease inhibitor primarily. As you can see on my lymphocytes progress chart, my T cells are no longer suppressed by SARS-COV2. Stribild helped by B cells, but Tollovid has made the difference for T cells. It can be used for acute or long COVID.
1
6
122
Gerald Commissiong retweeted
Someone asked if Tollovid was a prescription (the post disappeared). It's a supplement made from Gromwell root. I buy it through the Tollo Health website. If you get it, make sure to buy when it's buy one get one free- B1G1 is the current code. Sometimes i see bottles for sale for less on ebay. I now take 3 capsules 3 times daily, but started out on 4 times daily- this was the recommended dose for acute COVID. I've tried Hawaii Pharm's gromwell root tincture, but it didn't help me. My thyroid function was strangely suppressed while i was on it. There's another knockoff brand called Tollo19, but I have never tried it because the company wouldn't tell me if it was gluten and corn free.
1
1
8
302
Gerald Commissiong retweeted
OST-HER2 is being developed to deliver HER2-targeted antigens using a live-attenuated Listeria platform, helping train the immune system to recognize and respond to tumor cells. Explore more: bit.ly/3QcrvJy $OSTX
3
14
422
Gerald Commissiong retweeted
Emory University, 38 participants. Single cell profiling found Long COVID immune cells act as if they keep seeing antigen. B cells stayed activated, T cells showed exhaustion, and NK cells became dysfunctional, supporting persistent immune stimulation. biorxiv.org/content/10.64898…
2
81
295
9,409
Gerald Commissiong retweeted
Progress in osteosarcoma research depends on more than new therapies alone. A recent article from @DDWJournal explores how collaboration between researchers, regulators, clinicians and patient communities may help shape future approaches to rare pediatric cancer development. Read more: bit.ly/4egz2Q3 $OSTX
2
10
245
Gerald Commissiong retweeted
The anatomical proximity and direct connection between the olfactory bulb and the orbital prefrontal cortex (OFC) make it a key neuroinvasion route for #COVID in the brain. In patients with #NeuroCovid, we observe thrombotic events, hypometabolism and atrophy in this region.
Let's rip the band-aid off
21
283
766
29,707
Gerald Commissiong retweeted
OS Therapies achieved global regulatory alignment on the design of its Phase 3 trial of OST-HER2 in fully resected, pulmonary metastatic osteosarcoma. The confirmatory Phase 3 study is expected to commence in Q3 2026, supporting potential regulatory decisions in Q4 2026. Read more: bit.ly/49OxdZ7 $OSTX
4
11
235
Gerald Commissiong retweeted
Beyond brain fog: viral proteins as convergent drivers of neuroinflammation and proteinopathy 🚨“COVID-19 never really leaves your brain.” New science review proposes SARSCoV2 viral proteins stay behind as long-lived toxins, triggering chronic neuroinflammation and planting the seeds of Alzheimer’s and Parkinson’s, even after mild infection. This very interesting and eye-catching GERMAN review reframes post-viral neurological syndromes( L0ngC0vid) as driven by persistent viral proteins acting as long-term toxins ("protein-as-pathogen" model), not just the active infection! ➡️Core mechanisms: - SARSCoV2 Spike and OTHER viral proteins activate glial TLR4/TLR2 receptors, triggering chronic neuroinflammatory cascades via NLRP3 inflammasome, - They also disrupt autophagy, allowing toxic protein aggregates (tau, amyloid-beta, α-synuclein) to accumulate and seed neurodegeneration, ➡️SARSCoV2 specific evidence: - Animal studies show Spike protein alone (without live virus) induces TLR4-mediated cognitive deficits, memory impairment, synaptic loss, and sustained neuroinflammation, recapitulating post-COVID syndrome, - Spike binds α-synuclein, accelerating Parkinson-like clumps, ➡️Human data evidence: - Millions experience "brain fog," - Post-COVID patients exhibit measurable brain damage: cortical thinning, hippocampal iron accumulation, and biomarkers of ongoing neuronal injury, ➡️Broader risks: - Even mild infections leave lingering proteins that promote Alzheimer’s and Parkinson’s-like pathology via shared pathways, - Same pathways seen in influenza, dengue, West Nile etc, - Mild infection = no protection, ‼️So, according to this review, the “protein-as-pathogen” model makes it crystal clear: every new SARSCoV2 infection (even mild or asymptomatic) deposits more of these long-lived toxic viral proteins into the brain. They don’t fully clear. They accumulate. Each reinfection reloads the TLR4/TLR2 → NLRP3 inflammasome trigger and further collapses autophagy, speeding up the tau/amyloid/α-synuclein proteinopathy and neurodegeneration. SARS-CoV-2 does not just infect. It weaponizes its own proteins as long-lived intracellular saboteurs. Millions are probably already carrying this hidden payload. This is not brain fog. This is a silent, population-scale reprogramming of human brains toward dementia-like decline. The long-term neurological cost will probably dwarf the acute pandemic itself! #AvoidSars2 #AvoidReinfections sciencedirect.com/science/ar…
14
285
658
22,435
Gerald Commissiong retweeted
Good news. The FDA just approved ensitrelvir (Xocova, from Shionogi) for post-exposure prophylaxis of COVID-19. This is the first oral pill to help prevent infection after exposure. This was approved over 2 years ago in Japan. Great to have another preventative option available.
8
16
119
5,442
Gerald Commissiong retweeted
Children with Long COVID had measurable retinal microvascular changes. buff.ly/fPSg320 In 74 kids ages 7–17, scans found wider arterioles, wider venules, and a higher A/V ratio, consistent with endothelial dysfunction. The eye may help track pediatric Long COVID.
7
141
404
33,987
Gerald Commissiong retweeted
Search interest for illness at the world cup in the US is almost off the charts.
6
30
141
4,603
Gerald Commissiong retweeted
10 million Americans undiagnosed with disease that causes fatigue, brain fog and headaches: report trib.al/Zh3xIEs
78
56
352
4,001,452
Gerald Commissiong retweeted
New data from David Ho's lab showing that while adults & kids have ~equal antibody responses to XFG & NB.1.8.1, children have essentially no neutralizing antibodies to BA.3.2. This seems to largely solve the BA.3.2 kids mystery. 1/14
17
164
453
27,716
Gerald Commissiong retweeted
Recurrent osteosarcoma remains one of the most challenging pediatric and young adult cancers, with limited treatment options available for patients facing relapse. Accelerated approval pathways were designed to address urgent patient needs. Recurrent osteosarcoma may be one of the clearest examples of why these pathways matter. Read more via @DDWJournal: bit.ly/4u5TQzv
3
10
220
Gerald Commissiong retweeted
It was a pleasure connecting with partners and advocates at #ASCO2026! As the oncology community gathered to discuss the latest advances in cancer research and treatment, OS Therapies CEO Paul Romness and CBO Gerald Commissiong were pleased to spend time with our partners at Eversana and representatives from OsteoWarriors (MIB), discussing the ongoing need for innovation, advocacy, and improved outcomes for patients affected by osteosarcoma and other rare cancers. Thank you to everyone who joined the conversation. We look forward to continuing to collaborate to improve patient outcomes. $OSTX
2
11
286